Hospital Medicine Unplugged

In this episode of Hospital Medicine Unplugged, we race through delirium in hospitalized adults—spot it early, fix the causes, deploy bundles, and medicate only when safety’s at stake.We open with the scale and stakes: delirium hits ~11–42% of general inpatients and up to 87% of older surgical patients, driving falls, longer LOS, institutionalization, cognitive/functional decline, and higher mortality. Hypoactive phenotypes hide in plain sight—look for inattention + fluctuation.Diagnosis & risk stratification—make screening routine:• Bedside tools: CAM (and Short-CAM/3D-CAM), 4AT, CAM-S (severity).• Method: pair direct interview with chart review; anchor on acute onset, inattention, fluctuating course, ± disorganized thinking or altered consciousness.• Risk factors: age, baseline cognitive impairment, sensory loss, dehydration, sleep deprivation, polypharmacy (+ benzodiazepines/anticholinergics/opioids), infection, metabolic derangements.Prevention—build the nonpharmacologic bundle (it works):• Multicomponent programs cut incident delirium ~43–53% vs usual care.• Core moves: frequent reorientation & cognitive stimulation; early mobilization; sleep hygiene (cluster care, lights/noise control); hydrate & nourish; vision/hearing optimization (glasses, hearing aids); family engagement; minimize tethers/restraints.• Models: HELP on wards; ABCDEF in ICU (pain/light sedation, delirium monitoring, early mobility, family).Management—treat delirium like acute brain failure:• First line is always nonpharmacologic + rapid hunt/correct contributors: meds (de-prescribe anticholinergics/benzos when possible), hypoxia, infection, electrolyte/renal/hepatic issues, pain, urinary retention/constipation, withdrawal states.• Environment: daylight cues by day, quiet/dark at night; clocks/calendars; familiar objects; bladder/bowel care.• Mobilize early, restore circadian rhythm, avoid physical restraints whenever possible.When agitation endangers care or safety:• Antipsychotics (off-label) only for severe agitation: start low-dose haloperidol (e.g., 0.5–1 mg) or consider quetiapine/olanzapine if EPS/QTc risk; use the lowest effective dose for the shortest time. They do not shorten delirium—they just help you get through essential care safely.• Avoid benzodiazepines except for alcohol/benzo withdrawal.• Melatonin/ramelteon: mixed evidence; not routine.• Always re-evaluate daily and de-escalate fast.Setting-specific pearls:• ICU: screen with CAM-ICU/ICDSC; keep sedation light; dexmedetomidine may beat benzos for ventilated patients; execute ABCDEF.• Post-op: proactive geriatric co-management, opioid-sparing analgesia, regional techniques when appropriate, early mobilization/sleep protection.• Palliative/end-of-life: prioritize comfort and distress reduction; short courses of antipsychotic for severe symptoms after family-aligned goals-of-care discussions.Prognosis—why urgency matters:• Delirium tracks with higher in-hospital mortality, prolonged stays, discharge to facilities, and long-term cognitive decline; risk rises with duration of delirium.• Many episodes persist to discharge—plan for post-acute screening, rehab, and caregiver education.Medication pitfalls you don’t want to meet:• Reflex antipsychotic use without addressing causes.• Benzos outside withdrawal (↑ delirium, oversedation).• QT prolongation, EPS, orthostasis/falls—ECG & dose-low/go-slow in older adults.Research gaps we flag: which bundle elements matter most, pragmatic ways to scale HELP/ABCDEF across diverse hospitals, and safe pharmacologic options that actually shorten delirium.Bottom line: screen early, fix causes, deploy bundles, and reserve meds for danger—that’s how you prevent falls, shorten stays, and protect cognition.

In this episode of Hospital Medicine Unplugged, we tackle myocarditis in hospitalized patients—recognize fast, stratify risk, escalate support, and target therapy when needed.We start with the do-firsts: triage to the right care setting, exclude obstructive coronary artery disease, and launch diagnostic testing with ECG, hs-troponin, natriuretic peptides, CRP, and echocardiography. If the picture remains uncertain, CMR confirms inflammation and endomyocardial biopsy (EMB) is reserved for high-risk or atypical cases where histology can guide therapy.Risk stratification drives location of care:• Stable patients (preserved EF, no arrhythmias or instability) → general ward with monitoring.• High-risk patients (reduced EF, sustained arrhythmias, advanced AV block, cardiogenic shock, fulminant onset, or biopsy-proven giant cell/eosinophilic myocarditis) → ICU, where rapid deterioration and need for mechanical circulatory support is common.Supportive care anchors management. Remove inciting agents, maintain continuous monitoring, and manage chest pain cautiously (NSAIDs/colchicine if EF preserved, but avoid NSAIDs in heart failure/shock).For heart failure, follow guideline-directed therapy: diuretics, ACEi/ARB/ARNI, beta-blockers, MRA, SGLT2i as tolerated. Escalate to inotropes and temporary support (VA-ECMO, Impella, IABP) if cardiogenic shock persists. LVAD or transplant enter the discussion if recovery stalls.Arrhythmia management is essential:• Continuous telemetry for all.• Antiarrhythmics, pacing, or defibrillation for unstable rhythms.• ICD placement considered before discharge in select high-risk cases.Immunosuppression is targeted, not routine. Corticosteroids ± calcineurin inhibitors are reserved for biopsy-proven noninfectious immune-mediated myocarditis (giant cell, eosinophilic, sarcoid, immune checkpoint inhibitor–related). Viral PCR must guide therapy—avoid immunosuppression if active viral infection is present. Antivirals may be used in rare cases with proven viral triggers.Prognosis splits two ways:• Most uncomplicated cases (chest pain, preserved EF, no arrhythmias) recover fully, with excellent short- and long-term outcomes.• Severe presentations (shock, fulminant myocarditis, sustained arrhythmias, giant cell disease) carry in-hospital mortality or transplant rates of 8–28%, with long-term risk of progression to dilated cardiomyopathy, arrhythmias, or death in up to 25%.Follow-up is mandatory: early post-discharge visits, repeat echo at 2–4 weeks, CMR at 3–6 months in higher-risk patients, and strict exercise restriction for 3–6 months. Return-to-play requires normalized biomarkers, normal LV function, and arrhythmia-free surveillance.Key takeaways: recognize fast, risk-stratify, monitor aggressively, use CMR for diagnosis, biopsy selectively, treat heart failure per guidelines, immunosuppress only when indicated, and never miss fulminant disease. Most patients recover, but severe myocarditis demands escalation to advanced therapies and multidisciplinary care.

In this episode of Hospital Medicine Unplugged, we sprint through pericarditis—diagnose fast, cool the inflammation, prevent tamponade, crush recurrences.We open with the do-firsts: history/exam (rub), ECG, CRP/ESR + leukocytosis/fever, and TTE to size the effusion and exclude tamponade/constriction. CMR is reasonable in complicated/recurrent/incessant cases to confirm pericardial inflammation or myocardial involvement.Call the diagnosis when ≥2 of 4: typical chest pain, pericardial rub, diffuse ST↑/PR↓, new/worsening effusion. Support with ↑CRP and CMR LGE/pericardial edema when the picture is hazy.Risk-stratify for admission (any = admit): fever >38°C, subacute course, large effusion (>2 cm), tamponade, failed outpatient NSAIDs, immunosuppression/trauma, or suspected TB/malignancy. In-house: serial TTE and trend CRP.Treatment—build the anti-inflammatory backbone:• First-line: High-dose aspirin (650–1000 mg TID) or NSAID (e.g., ibuprofen 600–800 mg q8h) + colchicine (0.5–0.6 mg BID if >70 kg; QD if ≤70 kg) for 3 months (≥6 months for recurrent). Aspirin preferred if ischemic heart disease. Add PPI.• Exercise restriction: keep HR <100 and no strenuous activity for ≥1 month (longer with myopericarditis).If the backbone buckles:• Corticosteroids (pred 0.2–0.5 mg/kg/day) only when NSAID/colchicine fail or are contraindicated (autoimmune, pregnancy, etc.). Slow taper, CRP-guided—early steroids ↑ recurrence.• Anti–IL-1 (anakinra, rilonacept) for refractory/recurrent with inflammatory phenotype (↑CRP) after infection screen.• Azathioprine or IVIG if still refractory.• Radical pericardiectomy in high-volume centers for truly unresponsive disease.Etiology plays (treat the cause):• TB pericarditis: RIPE regimen; consider steroids if constrictive/inflammatory.• Uremic pericarditis: intensify dialysis.• Malignancy: oncologic therapy + tailored pericardial management.• Post–cardiac injury: standard NSAID + colchicine, cautious steroid use.Pericardial effusion & tamponade—don’t miss it: look for hypotension, JVD, pulsus paradoxus. Echo signs: RA/RV diastolic collapse, plethoric IVC, respiratory inflow variation. Action: emergent echo-guided pericardiocentesis with slow drainage; gentle IV fluids while prepping; avoid PPV if possible. For recurrent/purulent/neoplastic cases, pericardial window is reasonable. Always send fluid for cell count, Gram/culture, AFB/TB PCR, cytology.Monitoring & tapering that sticks: trend CRP to steer NSAID taper, check renal/hepatic function and CBC, and schedule serial TTE for moderate/large effusions. Colchicine adherence is your recurrence shield.Recurrence reality check: without prevention, ~30% recur. With colchicine, recurrences drop and remissions improve—finish the course. Keep activity limited until symptoms resolve + CRP normal.Medication pitfalls you don’t want to meet: early steroids (↑ recurrence), NSAID renal/GI toxicity (use PPI), dose-adjust colchicine in renal/hepatic impairment and watch for interactions (e.g., strong CYP3A4/P-gp inhibitors).We close with the system moves: a pericarditis bundle that (1) pre-checks ECG/CRP/TTE ± CMR; (2) defaults to NSAID(or aspirin) + colchicine + PPI with weight/renal dosing; (3) auto-admits high-risk features; (4) runs a CRP-guided taper and exercise-restriction protocol; (5) fires a tamponade pathway (STAT TTE → pericardiocentesis → full fluid studies); (6) launches a steroid-sparing track (early anti–IL-1 for recurrent/incessant); (7) routes to etiology-specific tracks (TB, uremia, malignancy, autoimmune) with multidisciplinary consults; (8) embeds lab safety monitoring.Fast, imaging-led, and recurrence-proof—build the NSAID+colchicine core, reserve steroids, treat the cause, and never miss tamponade.

In this episode of Hospital Medicine Unplugged, we sprint through inpatient VTE prevention—screen fast, prophylax right, and use system nudges so clots don’t slip through.We open with the do-firsts: risk-stratify at admission and again daily. Use Padua/IMPROVE for medical patients, Caprini for surgical; pair with a bleeding check (IMPROVE-Bleed or clinical gestalt). If high VTE risk and bleeding risk is acceptable, start chemoprophylaxis now; if bleeding risk is high or there’s active bleeding, go mechanical and reassess q24h. Don’t let missed doses happen.Prophylaxis decisions—match risk to modality:• Low VTE risk (Padua <4): Early ambulation, no routine anticoagulant.• High VTE risk + low bleed risk: Heparin-based prophylaxis (default).• High VTE risk + high bleed risk/contraindication: Intermittent pneumatic compression (IPC) until safe to switch to heparin.• Very high surgical risk (major ortho/onc): Plan extended duration per pathway.Pharmacologic playbook (in-hospital defaults):• UFH: 5,000 units SC q8–12h (handy for CrCl <30 mL/min, procedures expected).• LMWH (enoxaparin): 40 mg SC daily; 30 mg daily if CrCl <30. – Obesity: many centers use 40 mg BID or weight-based; follow local protocol.• Fondaparinux: 2.5 mg SC daily (avoid if CrCl <30, very low body weight, or neuraxial catheters).• Cancer inpatients/ICU: LMWH convenient; UFH if renal failure or frequent procedures.• Neuraxial anesthesia: time doses around catheter placement/removal; when in doubt, hold and ask anesthesia.When to hold anticoagulation (hit the brakes): active bleeding, platelets <50k, recent high-bleed-risk procedure, intracranial bleed/lesion, known/suspected HIT, severe coagulopathy (e.g., INR >2 not on warfarin), uncontrolled bleeding diathesis, or true heparin allergy. Use IPC and recheck daily to flip to heparin as soon as safe.Mechanical prophylaxis (when drugs are out—or as add-on):• IPC/SCDs fit to size, run ≥18 h/day, check skin each shift.• GCS only if IPC not tolerated and no PAD/skin risk.• Early ambulation helps but is not a standalone prophylaxis.Special situations:• Renal failure: Prefer UFH; if LMWH, renal-dose and monitor.• Obesity (BMI ≥40): Consider higher-intensity LMWH per protocol; add IPC in very high risk.• Orthopedic/major surgery: 10–35 days total prophylaxis depending on procedure/risk (LMWH/DOAC/aspirin per pathway).• Cancer surgery/inpatients: LMWH/UFH in hospital; consider extended prophylaxis post-op in high risk.• Stroke: Ischemic—usually prophylax unless tPA/bleed risk; hemorrhagic—mechanical first, then reassess.Monitoring and safety (make it boring-safe): daily VTE/bleed risk reassessment; don’t miss doses; trend hemoglobin/platelets (watch for HIT days 4–14 on heparin); watch renal function for dosing; confirm IPC adherence and skin integrity. Avoid routine DVT screening; investigate symptoms fast.Discharge and extended prophylaxis: not routine. Consider in select high-risk, low-bleed-risk medical patients (e.g., high IMPROVE/Padua with persistent immobility or elevated D-dimer) after weighing renal function, drug interactions, adherence, and cost. Set a clear stop date and follow-up plan.We close with the system moves: a VTE bundle that (1) auto-calculates Padua/IMPROVE/Caprini and proposes an order set; (2) defaults to LMWH with built-in renal/weight adjustments (UFH if CrCl <30); (3) hard-stops for major contraindications and fires IPC orders automatically; (4) pings teams on missed doses and day-4 platelet checks (HIT window); (5) prompts daily flip from IPC → heparin when safe; (6) runs surgical pathways for 10–35 day prophylaxis where indicated; (7) offers a discharge checker for truly high-risk, low-bleed candidates; (8) standardizes patient education to reduce refusals.Fast, risk-adapted, and system-supported—everything your team needs to prevent clots, avoid bleeds, and keep patients off the PE tightrope.

In this episode of Hospital Medicine Unplugged, we dive into metabolic acidosis—how to identify it quickly, match treatment to the underlying cause, and manage it effectively to avoid complications.We start by confirming the diagnosis—check arterial blood gas (ABG) and serum electrolytes for a low pH and bicarbonate (HCO₃⁻). Next, calculate the anion gap (use the formula: [Na⁺] – [Cl⁻] – [HCO₃⁻]) to classify it as high anion gap (e.g., lactic acidosis, diabetic ketoacidosis, uremia, toxins) or normal anion gap (hyperchloremic) (e.g., gastrointestinal bicarbonate loss, renal tubular acidosis, saline overuse). A urine anion gap can help distinguish renal vs. extrarenal causes.Now, let's treat the underlying cause:For high anion gap acidosis, you’ll need to address conditions like sepsis (with antibiotics), DKA (with insulin), or toxin ingestion (antidotes, possibly dialysis). In lactic acidosis, focus on correcting hypoperfusion and volume status.For normal anion gap acidosis, treat gastrointestinal losses (e.g., from diarrhea) or renal tubular acidosis. Saline overuse should be corrected with diuretics and reducing volume overload.When it comes to sodium bicarbonate therapy, it’s controversial. Studies show mixed results in mortality improvement, but it may help in severe acidemia (pH <7.2), especially in patients with acute kidney injury (AKI) or vasopressor dependency. But beware of risks like intracellular acidosis, hypocalcemia, hypernatremia, and volume overload. It’s not about full correction; it’s about getting the pH up to 7.2—slowly, with infusions rather than boluses.For severe or refractory cases, renal replacement therapy (RRT) is indicated, particularly in cases of lactic acidosis, severe renal dysfunction, or toxin clearance. Continuous modalities are ideal in unstable patients.In chronic metabolic acidosis (like CKD), use oral sodium bicarbonate to avoid serum bicarbonate falling below 18 mmol/L. Though it’s effective at increasing bicarbonate, there’s no conclusive evidence that correcting this prevents kidney failure progression.Don’t forget about monitoring—it’s key to assessing the response to therapy and managing electrolyte imbalances. Keep a close eye on potassium levels as correction of acidosis can cause hypokalemia. Regular assessment of ABG, lactate, and renal function helps guide the treatment.For prognosis, severe acidosis (pH <7.2) has a high mortality rate—especially with lactic acidosis or in critically ill patients. Early identification and targeted treatment are key to improving outcomes.We wrap up with a system move: automate the diagnosis with ABG and anion gap calculation, prioritize cause-specific treatment, and monitor closely for complications. If bicarbonate therapy is needed, slow infusions are the way to go—aiming for pH 7.2—and RRT for refractory cases.Metabolic acidosis requires rapid, accurate diagnosis and a tailored treatment plan. With the right strategy, you can optimize patient outcomes and prevent life-threatening complications.

In this episode of Hospital Medicine Unplugged, we dive deep into metabolic alkalosis, a common but often overlooked acid-base disturbance in hospitalized patients. From pathophysiology to evidence-based management, we’ll explore strategies for both acute and chronic cases, especially in critically ill patients.We begin with the fundamentals: metabolic alkalosis is defined by an elevated serum bicarbonate (HCO₃⁻) and arterial pH, with a compensatory increase in Pco₂. It's frequently seen in ICU patients, often due to diuretics, vomiting, or volume resuscitation. While mild cases are typically asymptomatic, severe alkalosis (pH >7.55) can lead to arrhythmias, neuromuscular irritability, and impaired tissue oxygenation—all contributing to increased morbidity and mortality.Pathophysiology: This condition arises from either a loss of fixed acid (like vomiting or diuretic use) or a net gain of alkali (exogenous bicarbonate). The kidneys usually excrete excess bicarbonate, but factors like volume contraction, hypokalemia, hypochloremia, and reduced GFR can impair this process, allowing alkalosis to persist. Common causes include gastric acid loss (e.g., vomiting), diuretics, mineralocorticoid excess, and genetic syndromes (e.g., Bartter, Gitelman).Diagnostic Approach: The key to diagnosis is a systematic acid-base assessment, starting with arterial blood gas analysis and serum electrolytes. A critical test is urine chloride measurement, which helps differentiate between chloride-responsive (<25 mmol/L) and chloride-resistant (>40 mmol/L) alkalosis. Correcting hypokalemia and hypochloremia is essential for all forms of metabolic alkalosis, and addressing underlying etiologies such as diuretic use or vomiting is crucial.Management:Chloride-responsive metabolic alkalosis (typically due to GI losses or diuretics): The cornerstone of therapy is volume repletion with isotonic saline and potassium replacement. This helps restore renal bicarbonate excretion and corrects hypokalemia and hypochloremia.Chloride-resistant metabolic alkalosis (e.g., mineralocorticoid excess): Here, the focus is on treating the underlying cause—such as using aldosterone antagonists (spironolactone) for primary hyperaldosteronism—and repleting potassium and magnesium.Severe or refractory alkalosis: In extreme cases (pH >7.60), acetazolamide (a carbonic anhydrase inhibitor) can help promote bicarbonate excretion. However, the benefits are mixed, and acid infusion (e.g., hydrochloric acid) or low-bicarbonate dialysis may be necessary for life-threatening cases.Special Considerations in critically ill patients:COPD and hypercapnia: Metabolic alkalosis can worsen respiratory failure in these patients by suppressing the respiratory drive. Acetazolamide may help in these cases, but it doesn't consistently improve mortality or ventilator duration. Careful management of diuretics and volume status is crucial.CHF and cirrhosis: Diuretic-induced alkalosis is common and can be worsened by neurohormonal activation. Treatment involves chloride and potassium repletion, minimizing diuretic use, and using aldosterone antagonists. For severe cases, acetazolamide may help, but close monitoring is required.Hospital-Specific Pearls:• Volume repletion is crucial for chloride-responsive alkalosis, and potassium supplementation should not be overlooked.• For chloride-resistant forms, aldosterone antagonists are a key treatment for mineralocorticoid excess, while acetazolamide is reserved for refractory cases.• Acid infusion or low-bicarbonate dialysis is only used in life-threatening alkalosis.• Special populations like COPD, CHF, and cirrhosis require tailored approaches, especially to avoid worsening respiratory failure.

In this episode of Hospital Medicine Unplugged, we discuss epistaxis—from initial management to preventing recurrence, with evidence-based strategies for hospitalized patients.We start with stabilization—the priority is always airway, breathing, and circulation. Massive epistaxis can compromise hemodynamic stability, so monitoring vital signs and ensuring hemodynamic support is crucial. Begin with digital compression of the lower third of the nose for 15-20 minutes and ensure the patient leans forward to prevent aspiration. This simple maneuver is often enough to control bleeding in many cases.If bleeding persists, we move to first-line therapies: apply topical vasoconstrictors like oxymetazoline or phenylephrine, which have proven effective in 65-75% of cases. Topical tranexamic acid (TXA) is a game-changer—studies show it's superior to traditional anterior packing for reducing rebleeding rates within 2 and 7 days. When the bleeding site is visible, electrocautery is the gold standard, leading to faster outcomes with reduced treatment times. If cautery fails, nasal packing is used, preferably resorbable for patients on anticoagulants to reduce trauma risk.For posterior epistaxis, which is more severe and often requires hospitalization, posterior packing or even balloon tamponade may be necessary. In refractory cases, arterial ligation or endovascular embolization are highly effective, with over 90% success in acute control.When managing special populations, such as those with hereditary hemorrhagic telangiectasia (HHT), ensure moisturizing therapies, and consider oral tranexamic acid or ablative therapies like laser or radiofrequency ablation for persistent bleeds. For anticoagulated patients, consider temporary reversal of anticoagulation if bleeding is severe.For discharge planning, focus on education about preventing recurrence—advise humidification and avoiding nasal trauma, and emphasize follow-up with otolaryngology for severe or recurrent cases. Patient education is vital to avoid further injury and to ensure early intervention if bleeding recurs.Hospital-specific pearls:• Prioritize airway safety and hemodynamic monitoring in all patients with epistaxis.• Use topical TXA as the first-line intervention for rebleeding, followed by electrocautery if the bleeding site is visible.• Resorbable nasal packing is preferred for anticoagulated patients to minimize trauma.• Early involvement of specialists—especially otolaryngologists—is crucial for severe or refractory cases.We close with system moves: a bundle that (1) triggers TXA administration in cases of epistaxis, (2) prompts electrocautery orders when the bleeding site is identified, (3) auto-orders resorbable packing for anticoagulated patients, (4) sends follow-up reminders for recurrent bleeds, and (5) links to specialist consultations for refractory or complex cases.Epistaxis care requires prompt diagnosis and intervention—with TXA, cautery, and packing as key components. Proper management reduces complications and improves patient comfort while preventing recurrence.

In this episode of Hospital Medicine Unplugged, we tackle compartment syndrome—diagnose early, intervene fast, and prevent long-term complications.We start with the essentials: pain management and serial assessments. The hallmark symptom is pain out of proportion to the injury. Administer analgesics promptly, but adjust based on the severity. For pain refractory to standard treatment, consider regional anesthesia or nerve blocks—but be cautious, as these may mask symptoms and delay diagnosis. Pain with passive stretch and paresthesias are critical early signs.Next, we focus on diagnosis—it’s all about clinical assessment and intracompartmental pressure (ICP) measurements. In cases where the exam is unreliable (e.g., sedated or unconscious patients), measure ICP. A pressure difference of <30 mmHg between diastolic blood pressure and compartment pressure is a strong indicator for fasciotomy. Remember, serial exams are crucial in high-risk patients—this condition is dynamic.Now, onto emergent treatment—fasciotomy is the only definitive option. Delays in intervention increase the risk of muscle necrosis, contractures, and permanent disability. Fasciotomy should aim for complete decompression of all affected compartments. Postoperative care includes wound care, infection prevention, and rehabilitation to prevent functional impairment and chronic pain.For long-term management, focus on rehabilitation. Early physical therapy helps prevent muscle atrophy and joint contractures. Multidisciplinary care involving orthopaedics, plastic surgery, and wound care specialists is essential for optimizing recovery and minimizing complications like infection and delayed healing.Hospital-specific pearls:• Early fasciotomy is key—don’t wait for imaging or lab results, act swiftly when diagnosis is clear.• Monitor pain and ICP measurements closely, especially in unconscious or non-communicative patients.• Coordinate early involvement of specialists like plastic surgery for wound management and rehabilitation for long-term recovery.• Avoid excessive sedation or regional anesthesia, as these may mask symptoms and delay diagnosis.We close with system moves: a bundle that (1) triggers early fasciotomy pathways in high-risk patients, (2) automates ICP measurement orders when clinical exams are unreliable, (3) links to multidisciplinary care teams for postoperative management, and (4) sets up follow-up reminders to monitor recovery and prevent complications.Compartment syndrome demands rapid diagnosis and intervention; proper pain management and complete decompression are essential for preventing irreversible injury—care that’s immediate on the wards and sustainable through rehabilitation.